Tyme Technologies, Inc. (TYME)

Trade TYME now with
9/15/2022 4:05:06 PM Syros And Tyme Technologies Announce Stockholder Approval Of Merger
7/5/2022 8:52:49 AM Syros Pharma To Buy Tyme Technologies
1/26/2022 6:55:40 AM TYME Technologies Announces Discontinuation Of SM-88 With MPS In Precision Promise Trial In Metastatic Pancreatic Cancer
12/14/2021 6:55:46 AM TYME Technologies Announces Encouraging Preclinical Data On Effect Of TYME-19 In SARS CoV-2 Infections
11/8/2021 7:00:49 AM TYME Technologies Q2 Net Loss $5.6 Mln Or $0.03/shr Vs Net Loss $6.9 Mln Or $0.05/shr Prior Year
9/27/2021 6:56:29 AM TYME Doses First Patient In Phase II OASIS Trial Of Oral SM-88 For Patients With Metastatic HR+/HER2- Breast Cancer
8/10/2021 6:52:47 AM TYME Technologies Q1 Net Loss $5.9 Mln Or $0.03/Shr Vs Loss Of $8.8 Mln Or $0.07/Shr Last Year
5/13/2021 9:08:15 AM TYME Technologies Appoints Frank Porfido As Its CFO
4/1/2021 8:06:38 AM Tyme Technologies Appoints Jan Van Tornout As Acting Chief Medical Officer